Daffodil
Senior Member
- Messages
- 5,875
with regular infusions, you would have no B cells!
Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
it gets rid of B cells. some of them are autoreactive..ie attacking the body
are the people who are giving rituximab giving antivirals right after it?
heap..since you are doing better on antivirals, you might do very well on rituximab if followed by antivirals to prevent reinfection of more B cells with EBV
but I don't know....my brain is mush
it gets rid of B cells. some of them are autoreactive..ie attacking the body
are the people who are giving rituximab giving antivirals right after it?
heap..since you are doing better on antivirals, you might do very well on rituximab if followed by antivirals to prevent reinfection of more B cells with EBV
but I don't know....my brain is mush
Rituximab 500 mg/m2 (maximum 1000 mg), diluted in saline to a concentration of 2 mg/ml, or an equal volume of saline, were given twice two weeks apart, with nurse surveillance and according to local guidelines used for treating B-cell lymphomas. No additional Rituximab infusions, or other intervention, were given during follow-up.
thanks deleder.
gave myself 6th infusion of gamunex last night. just getting worse with each one lol
Is Ampligen for sale, @heapsreal ?
No. At least not Rituximab. It is cost effective. Think of all the people that can get off disability schemes.
I agree for people getting of disability but i dont think alot of politicians can see that far ahead unfortunately.
If say, 70%, of patients treated with Rituximab can get back to work, politicians will get it. With a estimated 1 million M.E sufferers in the U.S, this could be what the U.S need to finally get out of their deficit lol. Remember that Rituximab is used to treat rheumatoid arthritis and other autoimmune diseases.
The patent is expired in Europe, and expires in the U.S in a few years. Prices will plummet.